Literature DB >> 28619957

Chronic pulmonary aspergillosis complicating sarcoidosis.

Yurdagül Uzunhan1,2, Hilario Nunes3,2, Florence Jeny3,2, Maxime Lacroix3,4, Sophie Brun5, Pierre-Yves Brillet3,4, Emmanuel Martinod6, Marie-France Carette7, Diane Bouvry3,2, Caroline Charlier8,9, Fanny Lanternier8,9, Carole Planès3,2, Abdellatif Tazi10, Olivier Lortholary8,9, Robert P Baughman11, Dominique Valeyre3,2.   

Abstract

Chronic pulmonary aspergillosis (CPA) complicating sarcoidosis (SA) is associated with high mortality, and there is a lack of clarity regarding the relative contributions of SA or CPA.This was a retrospective single-centre study on CPA-SA.In total, 65 patients (44 men), aged 41.4±13.5 and 48.3±11.9 years at the time of SA and CPA diagnoses, respectively, were included between 1980 and 2015. Of these, 64 had fibrocystic SA, most often advanced, with composite physiological index (CPI) >40 (65% of patients) and pulmonary hypertension (PH) (31%), and 41 patients (63%) were treated for SA (corticosteroids or immunosuppressive drugs). Chronic cavitary pulmonary aspergillosis (CCPA) was the most frequent CPA pattern. Regarding treatment, 55 patients required long-term antifungals, 14 interventional radiology, 11 resection surgery and two transplantation. Nearly half of the patients (27; 41.5%) died (mean age 55.8 years); 73% of the patients achieved 5-year survival and 61% 10-year survival. Death most often resulted from advanced SA and rarely from haemoptysis. CPI, fibrosis extent and PH predicted survival. Comparison with paired healthy controls without CPA did not show any difference in survival, but a higher percentage of patients had high-risk mould exposure.CPA occurs in advanced pulmonary SA. CPA-SA is associated with high mortality due to the underlying advanced SA rather than to the CPA. CPI, fibrosis extent and PH best predict outcome.
Copyright ©ERS 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28619957     DOI: 10.1183/13993003.02396-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  5 in total

1.  The indications for the treatment of sarcoidosis: Wells Law.

Authors:  Robert P Baughman; Marc A Judson; Athol Wells
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Differences in the clinical characteristics of chronic pulmonary aspergillosis according to spirometric impairment.

Authors:  Myoung Kyu Lee; Sae Byol Kim; Beomsu Shin
Journal:  PLoS One       Date:  2021-11-22       Impact factor: 3.240

3.  Clinical manifestations, associated risk factors and treatment outcomes of Chronic Pulmonary Aspergillosis (CPA): Experiences from a tertiary care hospital in Lahore, Pakistan.

Authors:  Waqas Akram; Muhammad Bilal Ejaz; Tauqeer Hussain Mallhi; Syed Azhar Bin Syed Sulaiman; Amer Hayat Khan
Journal:  PLoS One       Date:  2021-11-12       Impact factor: 3.240

Review 4.  Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns.

Authors:  Marc A Judson
Journal:  F1000Res       Date:  2019-12-30

Review 5.  A Comprehensive Review of Sarcoidosis Diagnosis and Monitoring for the Pulmonologist.

Authors:  Andrea S Melani; Albano Simona; Martina Armati; Miriana d'Alessandro; Elena Bargagli
Journal:  Pulm Ther       Date:  2021-06-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.